Section one: Contracting authority/entity
one.1) Name and addresses
NHS England - North East and Yorkshire
1W09, 1ST FLOOR, QUARRY HOUSE
Leeds
LS2 7UA
Country
United Kingdom
Region code
UKC - North East (England)
NHS Organisation Data Service
Y63
Internet address(es)
Main address
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Provision of Laboratory Services to Support the Delivery of the HPV Primary Screening Pathway within the NHS Cervical Screening Programme - North East and Yorkshire
two.1.2) Main CPV code
- 85145000 - Services provided by medical laboratories
two.1.3) Type of contract
Services
two.1.4) Short description
The aim of the NHS CSP is to reduce the incidence of, and mortality from, cervical cancer by delivering a systematic quality assured population-based screening programme for eligible people.
The aim of the Service is to support the delivery of the NHS CSP by testing samples and making direct referrals to colposcopy.
Section six. Complementary information
six.6) Original notice reference
Notice number: 2026/S 000-000303
Section seven. Changes
seven.1) Information to be changed or added
seven.2) Other additional information
This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. This contract has now been formally awarded using Direct Award Process C.
Contract Start Date: 01 July 2026
Contract End Date: 31 March 2029
Contract Value: £28,042,053
Details of the individuals/group making the award decision:
Head of Public Health & Strategic Commissioning - NHS England
Senior Public Health Commissioning Lead - NHS England
Senior Commissioning Manager - NHS England
North East and Yorkshire Public Health Commissioning Committee
The existing provider is satisfying the existing contract and will likely satisfy the proposed new contract. The provider has been assessed and passed against the relevant 5 key criteria and mandatory requirements.
There were no conflicts of interests identified.